Literature DB >> 32921745

Novel Coronavirus (SARS-CoV-2) resistance in African populations: A cause worth exploring.

Kewal Krishan1, Tanuj Kanchan2.   

Abstract

The pandemic caused by Novel Coronavirus SARS-CoV-2 shows its devastating effects all over the world. The American and the European countries are the worst-hit by this COVID-19 pandemic. However, most of the African countries excepting a few are less affected by this virus as far as the number of cases and deaths are concerned. The correspondence proposes that just like the abnormal haemoglobins HbS and HbC are found to provide immunity to the African populations against infectious diseases such as Plasmodium falciparum malaria The possibility of these abnormal haemoglobins offering certain protection against the Novel Coronavirus infection in these populations needs to be explored.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32921745      PMCID: PMC7717003          DOI: 10.23750/abm.v91i3.9872

Source DB:  PubMed          Journal:  Acta Biomed        ISSN: 0392-4203


  8 in total

1.  Protection afforded by sickle-cell trait against subtertian malareal infection.

Authors:  A C ALLISON
Journal:  Br Med J       Date:  1954-02-06

2.  Malaria continues to select for sickle cell trait in Central Africa.

Authors:  Eric Elguero; Lucrèce M Délicat-Loembet; Virginie Rougeron; Céline Arnathau; Benjamin Roche; Pierre Becquart; Jean-Paul Gonzalez; Dieudonné Nkoghe; Lucas Sica; Eric M Leroy; Patrick Durand; Francisco J Ayala; Benjamin Ollomo; François Renaud; Franck Prugnolle
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-04       Impact factor: 11.205

3.  Abnormal display of PfEMP-1 on erythrocytes carrying haemoglobin C may protect against malaria.

Authors:  Rick M Fairhurst; Dror I Baruch; Nathaniel J Brittain; Graciela R Ostera; John S Wallach; Holly L Hoang; Karen Hayton; Aldiouma Guindo; Morris O Makobongo; Owen M Schwartz; Anatole Tounkara; Ogobara K Doumbo; Dapa A Diallo; Hisashi Fujioka; May Ho; Thomas E Wellems
Journal:  Nature       Date:  2005-06-23       Impact factor: 49.962

Review 4.  Quinine, an old anti-malarial drug in a modern world: role in the treatment of malaria.

Authors:  Jane Achan; Ambrose O Talisuna; Annette Erhart; Adoke Yeka; James K Tibenderana; Frederick N Baliraine; Philip J Rosenthal; Umberto D'Alessandro
Journal:  Malar J       Date:  2011-05-24       Impact factor: 2.979

5.  Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors:  Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal:  Cell Res       Date:  2020-02-04       Impact factor: 25.617

6.  Sickle cell anaemia and malaria.

Authors:  Lucio Luzzatto
Journal:  Mediterr J Hematol Infect Dis       Date:  2012-10-03       Impact factor: 2.576

7.  Chloroquine and hydroxychloroquine as available weapons to fight COVID-19.

Authors:  Philippe Colson; Jean-Marc Rolain; Jean-Christophe Lagier; Philippe Brouqui; Didier Raoult
Journal:  Int J Antimicrob Agents       Date:  2020-03-04       Impact factor: 5.283

8.  In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors:  Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal:  Clin Infect Dis       Date:  2020-07-28       Impact factor: 9.079

  8 in total
  2 in total

1.  The regarding the call to explore the unexpected low severity of COVID-19 in Sub-Saharan Africa.

Authors:  Luis Fonte; Maria Ginori; Gissel García
Journal:  Acta Biomed       Date:  2020-11-10

Review 2.  COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis.

Authors:  Attilio Cavezzi; Roberto Menicagli; Emidio Troiani; Salvatore Corrao
Journal:  F1000Res       Date:  2022-01-27
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.